October MIMS Update

Guest Author 28/10/2025

Some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products Capivasertib (Truqap) is an inhibitor of the kinase activity of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2 and AKT3). AKT is a pivotal node in the phosphatidylinositol 3-kinase (PI3K) signalling cascade regulating multiple cellular processes including

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

October MIMS Update

Previous Empagliflozin PBS population expanded

Next Pharmacy presents united front on prescribing

MENU

ajp.com.au

Previous Empagliflozin PBS population expanded

Next Pharmacy presents united front on prescribing

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.